Susquehanna International Group, LLP Trevena Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$0.16 - $100.0 $11,408 - $7.13 Million	71,300 Added 17.06%	489,300 $73,000
Q2 2022 Aug 15, 2022	BUY	$0.2 - $0.5 $53,800 - $134,500	269,000 Added 180.54%	418,000 $171,000
Q1 2022 May 16, 2022	SELL	$0.41 - $0.63 $70,971 - $109,053	-173,100 Reduced 53.74%	149,000 $82,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $4,674 - $10,578	8,200 Added 2.61%	322,100 $187,000
Q3 2021 Nov 15, 2021	SELL	$1.11 - $1.7 $32,079 - $49,130	-28,900 Reduced 8.43%	313,900 $386,000
Q2 2021 Aug 11, 2021	SELL	$1.46 - $2.25 $283,386 - $436,725	-194,100 Reduced 36.15%	342,800 $579,000
Q1 2021 May 17, 2021	SELL	$1.77 - $2.93 $550,116 - $910,644	-310,800 Reduced 36.66%	536,900 $961,000
Q4 2020 Feb 16, 2021	BUY	$2.13 - $3.26 $536,547 - $821,194	251,900 Added 42.28%	847,700 $1.81 Million
Q3 2020 Nov 16, 2020	BUY	$1.53 - $3.13 $776,628 - $1.59 Million	507,600 Added 575.51%	595,800 $1.78 Million
Q2 2020 Aug 14, 2020	BUY	$0.48 - $1.75 $35,664 - $130,025	74,300 Added 534.53%	88,200 $132,000
Q4 2019 Feb 14, 2020	SELL	$0.62 - $1.06 $9,052 - $15,476	-14,600 Reduced 51.23%	13,900 $12,000
Q2 2019 Aug 14, 2019	SELL	$0.94 - $1.6 $123,046 - $209,440	-130,900 Reduced 82.12%	28,500 $29,000
Q1 2019 May 15, 2019	BUY	$0.51 - $1.88 $81,294 - $299,672	159,400 New	159,400 $249,000
Q4 2018 Feb 14, 2019	SELL	$0.39 - $3.47 $11,817 - $105,141	-30,300 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$1.39 - $2.25 $14,872 - $24,075	-10,700 Reduced 26.1%	30,300 $64,000
Q2 2018 Aug 14, 2018	BUY	$1.44 - $2.24 $59,040 - $91,840	41,000 New	41,000 $59,000

About TREVENA INC

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $313M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

More about TRVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account